N
NETRIS Pharma
Monoclonal antibodies overcoming cancer therapy resistance.
About NETRIS Pharma
Operator of a biopharmaceutical company intended to drive superior clinical benefits for patients in the treatment of cancer. The company's therapies work by targeting the dependence receptors to effectively restore the dependence receptor apoptosis signaling pathway in the absence of the required stimulus, enabling physicians and doctors to effectively cure cancers. Keywords: Pharmaceuticals and Biotechnology, Cancer Therapy, Cancer Treatment, Epithelial To Mesenchymal, Oncology Cure, Oncology Drug, Resistance To Treatment, Therapeutic Drug, Therapeutic Molecules, Therapy Research.
Source: Dealroom company dataAt a glance
- Founded
- 2008
- Headquarters
- Lyon, France
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
European Innovation Council
Horizon Europe
Series A1 investor entered at this stage
EIC Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NETRIS Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NETRIS Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.